ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Spinal Muscular Atrophy Medicine Market Research Report 2025
Published Date: January 2025
|
Report Code: QYRE-Auto-38V9738
Home | Market Reports | Health| Health Conditions| Neurological Conditions
Global Spinal Muscular Atrophy Medicine Market Insights Forecast to 2028
BUY CHAPTERS

Global Spinal Muscular Atrophy Medicine Market Research Report 2025

Code: QYRE-Auto-38V9738
Report
January 2025
Pages:102
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Astellas Pharma Inc
Avexis
Bioblast Pharma Ltd.
Cytokinetics, Inc. 24
F Hoffmann La Roche Ltd
Genethon
Genzyme Corporation
GMP-Orphan SAS
Ionis Pharmaceuticals Inc
Longevity Biotech Inc
Neurodyn Inc.
Neurotune AG
Novartis
Sarepta Therapeutics Inc
Voyager Therapeutics Inc
Vybion
WAVE Life Sciences Ltd

Spinal Muscular Atrophy Medicine Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Spinal Muscular Atrophy Medicine Market

Spinal Muscular Atrophy Medicine Market

The global market for Spinal Muscular Atrophy Medicine was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Spinal Muscular Atrophy Medicine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Spinal Muscular Atrophy Medicine.
The Spinal Muscular Atrophy Medicine market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Spinal Muscular Atrophy Medicine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Spinal Muscular Atrophy Medicine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Spinal Muscular Atrophy Medicine Market Report

Report Metric Details
Report Name Spinal Muscular Atrophy Medicine Market
CAGR 5%
Segment by Type
  • LMI-070
  • ND-602
  • NT-1654
  • Nusinersen
  • NXD-30001
  • Others
Segment by Application
  • Hospital
  • Clinic
  • Others
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Astellas Pharma Inc., AveXis, Inc., Bioblast Pharma Ltd., Cytokinetics, Inc. 24, F. Hoffmann-La Roche Ltd., Genethon, Genzyme Corporation, GMP-Orphan SAS, Ionis Pharmaceuticals, Inc., Longevity Biotech, Inc, Neurodyn Inc., Neurotune AG, Novartis AG, Sarepta Therapeutics, Inc., Voyager Therapeutics, Inc., Vybion, Inc., WAVE Life Sciences Ltd.
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Spinal Muscular Atrophy Medicine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Spinal Muscular Atrophy Medicine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Spinal Muscular Atrophy Medicine Market report?

Ans: The main players in the Spinal Muscular Atrophy Medicine Market are Astellas Pharma Inc., AveXis, Inc., Bioblast Pharma Ltd., Cytokinetics, Inc. 24, F. Hoffmann-La Roche Ltd., Genethon, Genzyme Corporation, GMP-Orphan SAS, Ionis Pharmaceuticals, Inc., Longevity Biotech, Inc, Neurodyn Inc., Neurotune AG, Novartis AG, Sarepta Therapeutics, Inc., Voyager Therapeutics, Inc., Vybion, Inc., WAVE Life Sciences Ltd.

What are the Application segmentation covered in the Spinal Muscular Atrophy Medicine Market report?

Ans: The Applications covered in the Spinal Muscular Atrophy Medicine Market report are Hospital, Clinic, Others

What are the Type segmentation covered in the Spinal Muscular Atrophy Medicine Market report?

Ans: The Types covered in the Spinal Muscular Atrophy Medicine Market report are LMI-070, ND-602, NT-1654, Nusinersen, NXD-30001, Others

Recommended Reports

Neuromuscular Disorders

Neurodegenerative Disease

Rare & Autoimmune Therapies

1 Spinal Muscular Atrophy Medicine Market Overview
1.1 Product Definition
1.2 Spinal Muscular Atrophy Medicine by Type
1.2.1 Global Spinal Muscular Atrophy Medicine Market Value Comparison by Type (2024 VS 2031)
1.2.2 LMI-070
1.2.3 ND-602
1.2.4 NT-1654
1.2.5 Nusinersen
1.2.6 NXD-30001
1.2.7 Others
1.3 Spinal Muscular Atrophy Medicine by Application
1.3.1 Global Spinal Muscular Atrophy Medicine Market Value by Application (2024 VS 2031)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Spinal Muscular Atrophy Medicine Market Size Estimates and Forecasts
1.4.1 Global Spinal Muscular Atrophy Medicine Revenue 2020-2031
1.4.2 Global Spinal Muscular Atrophy Medicine Sales 2020-2031
1.4.3 Global Spinal Muscular Atrophy Medicine Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Spinal Muscular Atrophy Medicine Market Competition by Manufacturers
2.1 Global Spinal Muscular Atrophy Medicine Sales Market Share by Manufacturers (2020-2025)
2.2 Global Spinal Muscular Atrophy Medicine Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Spinal Muscular Atrophy Medicine Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Spinal Muscular Atrophy Medicine, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Spinal Muscular Atrophy Medicine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Spinal Muscular Atrophy Medicine, Product Type & Application
2.7 Global Key Manufacturers of Spinal Muscular Atrophy Medicine, Date of Enter into This Industry
2.8 Global Spinal Muscular Atrophy Medicine Market Competitive Situation and Trends
2.8.1 Global Spinal Muscular Atrophy Medicine Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Spinal Muscular Atrophy Medicine Players Market Share by Revenue
2.8.3 Global Spinal Muscular Atrophy Medicine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Spinal Muscular Atrophy Medicine Market Scenario by Region
3.1 Global Spinal Muscular Atrophy Medicine Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Spinal Muscular Atrophy Medicine Sales by Region: 2020-2031
3.2.1 Global Spinal Muscular Atrophy Medicine Sales by Region: 2020-2025
3.2.2 Global Spinal Muscular Atrophy Medicine Sales by Region: 2026-2031
3.3 Global Spinal Muscular Atrophy Medicine Revenue by Region: 2020-2031
3.3.1 Global Spinal Muscular Atrophy Medicine Revenue by Region: 2020-2025
3.3.2 Global Spinal Muscular Atrophy Medicine Revenue by Region: 2026-2031
3.4 North America Spinal Muscular Atrophy Medicine Market Facts & Figures by Country
3.4.1 North America Spinal Muscular Atrophy Medicine Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Spinal Muscular Atrophy Medicine Sales by Country (2020-2031)
3.4.3 North America Spinal Muscular Atrophy Medicine Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Spinal Muscular Atrophy Medicine Market Facts & Figures by Country
3.5.1 Europe Spinal Muscular Atrophy Medicine Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Spinal Muscular Atrophy Medicine Sales by Country (2020-2031)
3.5.3 Europe Spinal Muscular Atrophy Medicine Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Spinal Muscular Atrophy Medicine Market Facts & Figures by Region
3.6.1 Asia Pacific Spinal Muscular Atrophy Medicine Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Spinal Muscular Atrophy Medicine Sales by Region (2020-2031)
3.6.3 Asia Pacific Spinal Muscular Atrophy Medicine Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Spinal Muscular Atrophy Medicine Market Facts & Figures by Country
3.7.1 Latin America Spinal Muscular Atrophy Medicine Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Spinal Muscular Atrophy Medicine Sales by Country (2020-2031)
3.7.3 Latin America Spinal Muscular Atrophy Medicine Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Spinal Muscular Atrophy Medicine Market Facts & Figures by Country
3.8.1 Middle East and Africa Spinal Muscular Atrophy Medicine Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Spinal Muscular Atrophy Medicine Sales by Country (2020-2031)
3.8.3 Middle East and Africa Spinal Muscular Atrophy Medicine Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Spinal Muscular Atrophy Medicine Sales by Type (2020-2031)
4.1.1 Global Spinal Muscular Atrophy Medicine Sales by Type (2020-2025)
4.1.2 Global Spinal Muscular Atrophy Medicine Sales by Type (2026-2031)
4.1.3 Global Spinal Muscular Atrophy Medicine Sales Market Share by Type (2020-2031)
4.2 Global Spinal Muscular Atrophy Medicine Revenue by Type (2020-2031)
4.2.1 Global Spinal Muscular Atrophy Medicine Revenue by Type (2020-2025)
4.2.2 Global Spinal Muscular Atrophy Medicine Revenue by Type (2026-2031)
4.2.3 Global Spinal Muscular Atrophy Medicine Revenue Market Share by Type (2020-2031)
4.3 Global Spinal Muscular Atrophy Medicine Price by Type (2020-2031)
5 Segment by Application
5.1 Global Spinal Muscular Atrophy Medicine Sales by Application (2020-2031)
5.1.1 Global Spinal Muscular Atrophy Medicine Sales by Application (2020-2025)
5.1.2 Global Spinal Muscular Atrophy Medicine Sales by Application (2026-2031)
5.1.3 Global Spinal Muscular Atrophy Medicine Sales Market Share by Application (2020-2031)
5.2 Global Spinal Muscular Atrophy Medicine Revenue by Application (2020-2031)
5.2.1 Global Spinal Muscular Atrophy Medicine Revenue by Application (2020-2025)
5.2.2 Global Spinal Muscular Atrophy Medicine Revenue by Application (2026-2031)
5.2.3 Global Spinal Muscular Atrophy Medicine Revenue Market Share by Application (2020-2031)
5.3 Global Spinal Muscular Atrophy Medicine Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Astellas Pharma Inc.
6.1.1 Astellas Pharma Inc. Company Information
6.1.2 Astellas Pharma Inc. Description and Business Overview
6.1.3 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Product Portfolio
6.1.5 Astellas Pharma Inc. Recent Developments/Updates
6.2 AveXis, Inc.
6.2.1 AveXis, Inc. Company Information
6.2.2 AveXis, Inc. Description and Business Overview
6.2.3 AveXis, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2020-2025)
6.2.4 AveXis, Inc. Spinal Muscular Atrophy Medicine Product Portfolio
6.2.5 AveXis, Inc. Recent Developments/Updates
6.3 Bioblast Pharma Ltd.
6.3.1 Bioblast Pharma Ltd. Company Information
6.3.2 Bioblast Pharma Ltd. Description and Business Overview
6.3.3 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Product Portfolio
6.3.5 Bioblast Pharma Ltd. Recent Developments/Updates
6.4 Cytokinetics, Inc. 24
6.4.1 Cytokinetics, Inc. 24 Company Information
6.4.2 Cytokinetics, Inc. 24 Description and Business Overview
6.4.3 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Product Portfolio
6.4.5 Cytokinetics, Inc. 24 Recent Developments/Updates
6.5 F. Hoffmann-La Roche Ltd.
6.5.1 F. Hoffmann-La Roche Ltd. Company Information
6.5.2 F. Hoffmann-La Roche Ltd. Description and Business Overview
6.5.3 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2020-2025)
6.5.4 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Product Portfolio
6.5.5 F. Hoffmann-La Roche Ltd. Recent Developments/Updates
6.6 Genethon
6.6.1 Genethon Company Information
6.6.2 Genethon Description and Business Overview
6.6.3 Genethon Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Genethon Spinal Muscular Atrophy Medicine Product Portfolio
6.6.5 Genethon Recent Developments/Updates
6.7 Genzyme Corporation
6.7.1 Genzyme Corporation Company Information
6.7.2 Genzyme Corporation Description and Business Overview
6.7.3 Genzyme Corporation Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Genzyme Corporation Spinal Muscular Atrophy Medicine Product Portfolio
6.7.5 Genzyme Corporation Recent Developments/Updates
6.8 GMP-Orphan SAS
6.8.1 GMP-Orphan SAS Company Information
6.8.2 GMP-Orphan SAS Description and Business Overview
6.8.3 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2020-2025)
6.8.4 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Product Portfolio
6.8.5 GMP-Orphan SAS Recent Developments/Updates
6.9 Ionis Pharmaceuticals, Inc.
6.9.1 Ionis Pharmaceuticals, Inc. Company Information
6.9.2 Ionis Pharmaceuticals, Inc. Description and Business Overview
6.9.3 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Product Portfolio
6.9.5 Ionis Pharmaceuticals, Inc. Recent Developments/Updates
6.10 Longevity Biotech, Inc
6.10.1 Longevity Biotech, Inc Company Information
6.10.2 Longevity Biotech, Inc Description and Business Overview
6.10.3 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Product Portfolio
6.10.5 Longevity Biotech, Inc Recent Developments/Updates
6.11 Neurodyn Inc.
6.11.1 Neurodyn Inc. Company Information
6.11.2 Neurodyn Inc. Description and Business Overview
6.11.3 Neurodyn Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Neurodyn Inc. Spinal Muscular Atrophy Medicine Product Portfolio
6.11.5 Neurodyn Inc. Recent Developments/Updates
6.12 Neurotune AG
6.12.1 Neurotune AG Company Information
6.12.2 Neurotune AG Description and Business Overview
6.12.3 Neurotune AG Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Neurotune AG Spinal Muscular Atrophy Medicine Product Portfolio
6.12.5 Neurotune AG Recent Developments/Updates
6.13 Novartis AG
6.13.1 Novartis AG Company Information
6.13.2 Novartis AG Description and Business Overview
6.13.3 Novartis AG Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Novartis AG Spinal Muscular Atrophy Medicine Product Portfolio
6.13.5 Novartis AG Recent Developments/Updates
6.14 Sarepta Therapeutics, Inc.
6.14.1 Sarepta Therapeutics, Inc. Company Information
6.14.2 Sarepta Therapeutics, Inc. Description and Business Overview
6.14.3 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Portfolio
6.14.5 Sarepta Therapeutics, Inc. Recent Developments/Updates
6.15 Voyager Therapeutics, Inc.
6.15.1 Voyager Therapeutics, Inc. Company Information
6.15.2 Voyager Therapeutics, Inc. Description and Business Overview
6.15.3 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Portfolio
6.15.5 Voyager Therapeutics, Inc. Recent Developments/Updates
6.16 Vybion, Inc.
6.16.1 Vybion, Inc. Company Information
6.16.2 Vybion, Inc. Description and Business Overview
6.16.3 Vybion, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2020-2025)
6.16.4 Vybion, Inc. Spinal Muscular Atrophy Medicine Product Portfolio
6.16.5 Vybion, Inc. Recent Developments/Updates
6.17 WAVE Life Sciences Ltd.
6.17.1 WAVE Life Sciences Ltd. Company Information
6.17.2 WAVE Life Sciences Ltd. Description and Business Overview
6.17.3 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2020-2025)
6.17.4 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Product Portfolio
6.17.5 WAVE Life Sciences Ltd. Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Spinal Muscular Atrophy Medicine Industry Chain Analysis
7.2 Spinal Muscular Atrophy Medicine Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Spinal Muscular Atrophy Medicine Production Mode & Process Analysis
7.4 Spinal Muscular Atrophy Medicine Sales and Marketing
7.4.1 Spinal Muscular Atrophy Medicine Sales Channels
7.4.2 Spinal Muscular Atrophy Medicine Distributors
7.5 Spinal Muscular Atrophy Medicine Customer Analysis
8 Spinal Muscular Atrophy Medicine Market Dynamics
8.1 Spinal Muscular Atrophy Medicine Industry Trends
8.2 Spinal Muscular Atrophy Medicine Market Drivers
8.3 Spinal Muscular Atrophy Medicine Market Challenges
8.4 Spinal Muscular Atrophy Medicine Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Astellas Pharma Inc
Avexis
Bioblast Pharma Ltd.
Cytokinetics, Inc. 24
F Hoffmann La Roche Ltd
Genethon
Genzyme Corporation
GMP-Orphan SAS
Ionis Pharmaceuticals Inc
Longevity Biotech Inc
Neurodyn Inc.
Neurotune AG
Novartis
Sarepta Therapeutics Inc
Voyager Therapeutics Inc
Vybion
WAVE Life Sciences Ltd
List of Tables
 Table 1. Global Spinal Muscular Atrophy Medicine Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Spinal Muscular Atrophy Medicine Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Spinal Muscular Atrophy Medicine Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Spinal Muscular Atrophy Medicine Sales (K Pcs) of Key Manufacturers (2020-2025)
 Table 5. Global Spinal Muscular Atrophy Medicine Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Spinal Muscular Atrophy Medicine Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Spinal Muscular Atrophy Medicine Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Spinal Muscular Atrophy Medicine Average Price (USD/Pcs) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Spinal Muscular Atrophy Medicine, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Spinal Muscular Atrophy Medicine, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Spinal Muscular Atrophy Medicine, Product Type & Application
 Table 12. Global Key Manufacturers of Spinal Muscular Atrophy Medicine, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Spinal Muscular Atrophy Medicine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Spinal Muscular Atrophy Medicine as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Spinal Muscular Atrophy Medicine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Spinal Muscular Atrophy Medicine Sales by Region (2020-2025) & (K Pcs)
 Table 18. Global Spinal Muscular Atrophy Medicine Sales Market Share by Region (2020-2025)
 Table 19. Global Spinal Muscular Atrophy Medicine Sales by Region (2026-2031) & (K Pcs)
 Table 20. Global Spinal Muscular Atrophy Medicine Sales Market Share by Region (2026-2031)
 Table 21. Global Spinal Muscular Atrophy Medicine Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Region (2020-2025)
 Table 23. Global Spinal Muscular Atrophy Medicine Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Region (2026-2031)
 Table 25. North America Spinal Muscular Atrophy Medicine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Spinal Muscular Atrophy Medicine Sales by Country (2020-2025) & (K Pcs)
 Table 27. North America Spinal Muscular Atrophy Medicine Sales by Country (2026-2031) & (K Pcs)
 Table 28. North America Spinal Muscular Atrophy Medicine Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Spinal Muscular Atrophy Medicine Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Spinal Muscular Atrophy Medicine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Spinal Muscular Atrophy Medicine Sales by Country (2020-2025) & (K Pcs)
 Table 32. Europe Spinal Muscular Atrophy Medicine Sales by Country (2026-2031) & (K Pcs)
 Table 33. Europe Spinal Muscular Atrophy Medicine Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Spinal Muscular Atrophy Medicine Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Spinal Muscular Atrophy Medicine Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Spinal Muscular Atrophy Medicine Sales by Region (2020-2025) & (K Pcs)
 Table 37. Asia Pacific Spinal Muscular Atrophy Medicine Sales by Region (2026-2031) & (K Pcs)
 Table 38. Asia Pacific Spinal Muscular Atrophy Medicine Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Spinal Muscular Atrophy Medicine Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Spinal Muscular Atrophy Medicine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Spinal Muscular Atrophy Medicine Sales by Country (2020-2025) & (K Pcs)
 Table 42. Latin America Spinal Muscular Atrophy Medicine Sales by Country (2026-2031) & (K Pcs)
 Table 43. Latin America Spinal Muscular Atrophy Medicine Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Spinal Muscular Atrophy Medicine Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Spinal Muscular Atrophy Medicine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Spinal Muscular Atrophy Medicine Sales by Country (2020-2025) & (K Pcs)
 Table 47. Middle East and Africa Spinal Muscular Atrophy Medicine Sales by Country (2026-2031) & (K Pcs)
 Table 48. Middle East and Africa Spinal Muscular Atrophy Medicine Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Spinal Muscular Atrophy Medicine Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Spinal Muscular Atrophy Medicine Sales (K Pcs) by Type (2020-2025)
 Table 51. Global Spinal Muscular Atrophy Medicine Sales (K Pcs) by Type (2026-2031)
 Table 52. Global Spinal Muscular Atrophy Medicine Sales Market Share by Type (2020-2025)
 Table 53. Global Spinal Muscular Atrophy Medicine Sales Market Share by Type (2026-2031)
 Table 54. Global Spinal Muscular Atrophy Medicine Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Spinal Muscular Atrophy Medicine Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Type (2020-2025)
 Table 57. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Type (2026-2031)
 Table 58. Global Spinal Muscular Atrophy Medicine Price (USD/Pcs) by Type (2020-2025)
 Table 59. Global Spinal Muscular Atrophy Medicine Price (USD/Pcs) by Type (2026-2031)
 Table 60. Global Spinal Muscular Atrophy Medicine Sales (K Pcs) by Application (2020-2025)
 Table 61. Global Spinal Muscular Atrophy Medicine Sales (K Pcs) by Application (2026-2031)
 Table 62. Global Spinal Muscular Atrophy Medicine Sales Market Share by Application (2020-2025)
 Table 63. Global Spinal Muscular Atrophy Medicine Sales Market Share by Application (2026-2031)
 Table 64. Global Spinal Muscular Atrophy Medicine Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Spinal Muscular Atrophy Medicine Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Application (2020-2025)
 Table 67. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Application (2026-2031)
 Table 68. Global Spinal Muscular Atrophy Medicine Price (USD/Pcs) by Application (2020-2025)
 Table 69. Global Spinal Muscular Atrophy Medicine Price (USD/Pcs) by Application (2026-2031)
 Table 70. Astellas Pharma Inc. Company Information
 Table 71. Astellas Pharma Inc. Description and Business Overview
 Table 72. Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 73. Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Product
 Table 74. Astellas Pharma Inc. Recent Developments/Updates
 Table 75. AveXis, Inc. Company Information
 Table 76. AveXis, Inc. Description and Business Overview
 Table 77. AveXis, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 78. AveXis, Inc. Spinal Muscular Atrophy Medicine Product
 Table 79. AveXis, Inc. Recent Developments/Updates
 Table 80. Bioblast Pharma Ltd. Company Information
 Table 81. Bioblast Pharma Ltd. Description and Business Overview
 Table 82. Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 83. Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Product
 Table 84. Bioblast Pharma Ltd. Recent Developments/Updates
 Table 85. Cytokinetics, Inc. 24 Company Information
 Table 86. Cytokinetics, Inc. 24 Description and Business Overview
 Table 87. Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 88. Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Product
 Table 89. Cytokinetics, Inc. 24 Recent Developments/Updates
 Table 90. F. Hoffmann-La Roche Ltd. Company Information
 Table 91. F. Hoffmann-La Roche Ltd. Description and Business Overview
 Table 92. F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 93. F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Product
 Table 94. F. Hoffmann-La Roche Ltd. Recent Developments/Updates
 Table 95. Genethon Company Information
 Table 96. Genethon Description and Business Overview
 Table 97. Genethon Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 98. Genethon Spinal Muscular Atrophy Medicine Product
 Table 99. Genethon Recent Developments/Updates
 Table 100. Genzyme Corporation Company Information
 Table 101. Genzyme Corporation Description and Business Overview
 Table 102. Genzyme Corporation Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 103. Genzyme Corporation Spinal Muscular Atrophy Medicine Product
 Table 104. Genzyme Corporation Recent Developments/Updates
 Table 105. GMP-Orphan SAS Company Information
 Table 106. GMP-Orphan SAS Description and Business Overview
 Table 107. GMP-Orphan SAS Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 108. GMP-Orphan SAS Spinal Muscular Atrophy Medicine Product
 Table 109. GMP-Orphan SAS Recent Developments/Updates
 Table 110. Ionis Pharmaceuticals, Inc. Company Information
 Table 111. Ionis Pharmaceuticals, Inc. Description and Business Overview
 Table 112. Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 113. Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Product
 Table 114. Ionis Pharmaceuticals, Inc. Recent Developments/Updates
 Table 115. Longevity Biotech, Inc Company Information
 Table 116. Longevity Biotech, Inc Description and Business Overview
 Table 117. Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 118. Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Product
 Table 119. Longevity Biotech, Inc Recent Developments/Updates
 Table 120. Neurodyn Inc. Company Information
 Table 121. Neurodyn Inc. Description and Business Overview
 Table 122. Neurodyn Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 123. Neurodyn Inc. Spinal Muscular Atrophy Medicine Product
 Table 124. Neurodyn Inc. Recent Developments/Updates
 Table 125. Neurotune AG Company Information
 Table 126. Neurotune AG Description and Business Overview
 Table 127. Neurotune AG Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 128. Neurotune AG Spinal Muscular Atrophy Medicine Product
 Table 129. Neurotune AG Recent Developments/Updates
 Table 130. Novartis AG Company Information
 Table 131. Novartis AG Description and Business Overview
 Table 132. Novartis AG Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 133. Novartis AG Spinal Muscular Atrophy Medicine Product
 Table 134. Novartis AG Recent Developments/Updates
 Table 135. Sarepta Therapeutics, Inc. Company Information
 Table 136. Sarepta Therapeutics, Inc. Description and Business Overview
 Table 137. Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 138. Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product
 Table 139. Sarepta Therapeutics, Inc. Recent Developments/Updates
 Table 140. Voyager Therapeutics, Inc. Company Information
 Table 141. Voyager Therapeutics, Inc. Description and Business Overview
 Table 142. Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 143. Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product
 Table 144. Voyager Therapeutics, Inc. Recent Developments/Updates
 Table 145. Vybion, Inc. Company Information
 Table 146. Vybion, Inc. Description and Business Overview
 Table 147. Vybion, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 148. Vybion, Inc. Spinal Muscular Atrophy Medicine Product
 Table 149. Vybion, Inc. Recent Developments/Updates
 Table 150. WAVE Life Sciences Ltd. Company Information
 Table 151. WAVE Life Sciences Ltd. Description and Business Overview
 Table 152. WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 153. WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Product
 Table 154. WAVE Life Sciences Ltd. Recent Developments/Updates
 Table 155. Key Raw Materials Lists
 Table 156. Raw Materials Key Suppliers Lists
 Table 157. Spinal Muscular Atrophy Medicine Distributors List
 Table 158. Spinal Muscular Atrophy Medicine Customers List
 Table 159. Spinal Muscular Atrophy Medicine Market Trends
 Table 160. Spinal Muscular Atrophy Medicine Market Drivers
 Table 161. Spinal Muscular Atrophy Medicine Market Challenges
 Table 162. Spinal Muscular Atrophy Medicine Market Restraints
 Table 163. Research Programs/Design for This Report
 Table 164. Key Data Information from Secondary Sources
 Table 165. Key Data Information from Primary Sources
 Table 166. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Spinal Muscular Atrophy Medicine
 Figure 2. Global Spinal Muscular Atrophy Medicine Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Spinal Muscular Atrophy Medicine Market Share by Type: 2024 & 2031
 Figure 4. LMI-070 Product Picture
 Figure 5. ND-602 Product Picture
 Figure 6. NT-1654 Product Picture
 Figure 7. Nusinersen Product Picture
 Figure 8. NXD-30001 Product Picture
 Figure 9. Others Product Picture
 Figure 10. Global Spinal Muscular Atrophy Medicine Market Value by Application (2020-2031) & (US$ Million)
 Figure 11. Global Spinal Muscular Atrophy Medicine Market Share by Application: 2024 & 2031
 Figure 12. Hospital
 Figure 13. Clinic
 Figure 14. Others
 Figure 15. Global Spinal Muscular Atrophy Medicine Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 16. Global Spinal Muscular Atrophy Medicine Market Size (2020-2031) & (US$ Million)
 Figure 17. Global Spinal Muscular Atrophy Medicine Sales (2020-2031) & (K Pcs)
 Figure 18. Global Spinal Muscular Atrophy Medicine Average Price (USD/Pcs) & (2020-2031)
 Figure 19. Spinal Muscular Atrophy Medicine Report Years Considered
 Figure 20. Spinal Muscular Atrophy Medicine Sales Share by Manufacturers in 2024
 Figure 21. Global Spinal Muscular Atrophy Medicine Revenue Share by Manufacturers in 2024
 Figure 22. Global 5 and 10 Largest Spinal Muscular Atrophy Medicine Players: Market Share by Revenue in Spinal Muscular Atrophy Medicine in 2024
 Figure 23. Spinal Muscular Atrophy Medicine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 24. Global Spinal Muscular Atrophy Medicine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 25. North America Spinal Muscular Atrophy Medicine Sales Market Share by Country (2020-2031)
 Figure 26. North America Spinal Muscular Atrophy Medicine Revenue Market Share by Country (2020-2031)
 Figure 27. U.S. Spinal Muscular Atrophy Medicine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. Canada Spinal Muscular Atrophy Medicine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. Europe Spinal Muscular Atrophy Medicine Sales Market Share by Country (2020-2031)
 Figure 30. Europe Spinal Muscular Atrophy Medicine Revenue Market Share by Country (2020-2031)
 Figure 31. Germany Spinal Muscular Atrophy Medicine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. France Spinal Muscular Atrophy Medicine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. U.K. Spinal Muscular Atrophy Medicine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Italy Spinal Muscular Atrophy Medicine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. Russia Spinal Muscular Atrophy Medicine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. Asia Pacific Spinal Muscular Atrophy Medicine Sales Market Share by Region (2020-2031)
 Figure 37. Asia Pacific Spinal Muscular Atrophy Medicine Revenue Market Share by Region (2020-2031)
 Figure 38. China Spinal Muscular Atrophy Medicine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. Japan Spinal Muscular Atrophy Medicine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. South Korea Spinal Muscular Atrophy Medicine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. India Spinal Muscular Atrophy Medicine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Australia Spinal Muscular Atrophy Medicine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Taiwan Spinal Muscular Atrophy Medicine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Indonesia Spinal Muscular Atrophy Medicine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Thailand Spinal Muscular Atrophy Medicine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Malaysia Spinal Muscular Atrophy Medicine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Philippines Spinal Muscular Atrophy Medicine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Latin America Spinal Muscular Atrophy Medicine Sales Market Share by Country (2020-2031)
 Figure 49. Latin America Spinal Muscular Atrophy Medicine Revenue Market Share by Country (2020-2031)
 Figure 50. Mexico Spinal Muscular Atrophy Medicine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Brazil Spinal Muscular Atrophy Medicine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. Argentina Spinal Muscular Atrophy Medicine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Middle East and Africa Spinal Muscular Atrophy Medicine Sales Market Share by Country (2020-2031)
 Figure 54. Middle East and Africa Spinal Muscular Atrophy Medicine Revenue Market Share by Country (2020-2031)
 Figure 55. Turkey Spinal Muscular Atrophy Medicine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 56. Saudi Arabia Spinal Muscular Atrophy Medicine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 57. U.A.E Spinal Muscular Atrophy Medicine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 58. Global Sales Market Share of Spinal Muscular Atrophy Medicine by Type (2020-2031)
 Figure 59. Global Revenue Market Share of Spinal Muscular Atrophy Medicine by Type (2020-2031)
 Figure 60. Global Spinal Muscular Atrophy Medicine Price (USD/Pcs) by Type (2020-2031)
 Figure 61. Global Sales Market Share of Spinal Muscular Atrophy Medicine by Application (2020-2031)
 Figure 62. Global Revenue Market Share of Spinal Muscular Atrophy Medicine by Application (2020-2031)
 Figure 63. Global Spinal Muscular Atrophy Medicine Price (USD/Pcs) by Application (2020-2031)
 Figure 64. Spinal Muscular Atrophy Medicine Value Chain
 Figure 65. Channels of Distribution (Direct Vs Distribution)
 Figure 66. Bottom-up and Top-down Approaches for This Report
 Figure 67. Data Triangulation
 Figure 68. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Seventh Sense AI

SIMILAR REPORTS

Global Multiple System Atrophy Therapeutics Market Research Report 2024
Global Becker Muscular Dystrophy Drug Market Research Report 2024
Spinal Muscular Atrophy SMA Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Skeletal Muscular Relaxants Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Myotonic Muscular Dystrophy DMD Treatments Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Duchenne Muscular Dystrophy Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Neurodegenerative Disease Treatment Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Muscle Spasm Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Bulbospinal Muscular Atrophy Drugs Market Research Report 2024
Muscle Spasm Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Myotubular Myopathy Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Scleroderma Treatment Market Research Report 2025
Neurodegenerative Diseases Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Spasticity Treatment Market Research Report 2025
Global Systemic Sclerosis Drug Market Research Report 2025
Global Autoimmune Diseases Treatment Market Research Report 2024
Periodic Paralysis Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Myotonic Dystrophy Type 1 DM1 Market Research Report 2025
Spinal and Bulbar Muscular Atrophy Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Musculoskeletal Disorders Therapeutics Market Research Report 2025
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions